Navigation Links
Therapure Biopharma Inc. Commissions its Commercial-Scale Lyophilizer

Freeze-drying of biopharmaceuticals now available at the Company’s Health Canada licensed facility.

Toronto, ON (PRWEB) Jan. 27, 2010 -- Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has completing the commissioning and validation of its commercial-scale pharmaceutical-grade freeze dryer and now offers commercial scale freeze drying (lyophilization) for contract manufacturing of biopharmaceuticals.

Lyophilization is used to convert biopharmaceuticals that are manufactured in an unstable liquid format into a stable, dry powder that can be reconstituted to a liquid format for administration to patients. Lyophilized forms of these life-saving products are more easily handled and stable than their liquid forms and therefore lyophilization is commonly used in the manufacture of these products.

“Until today, commercial-scale lyophilization has not been readily available in Canada,” said Mr. Wellner. “The launch of our commercial-scale lyophilizer, combined with our existing aseptic filling capabilities in vials and bags, significantly broadens the service offering we have for clients,” Mr. Wellner continued.

The new lyophilizer has been integrated into Therapure’s existing aseptic vial filling suite. This integrated suite now includes an automated vial filler, vial transporter, and the 75 square foot lyophilizer. All parts of this automated suite are contained within Class 100 clean space and are fully compliant with Health Canada and FDA GMP requirements The fill suite handles fill volumes ranging from 2ml to 200ml in glass vials with rubber stoppers and capped, and is capable of batch sizes ranging from 35,000 units per shift for smaller vials to 3,000 units per shift for larger vials.

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit:

Media Contact:

Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905-286-6204


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
3. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
4. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
5. Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
6. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
7. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
8. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
9. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
11. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... continuing education course in Dallas, TX, on January 29 and 30, 2016. The ... improve the functions of their practices, to learn how to better succeed in ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus ... Georgia State University. , Their study showed that small molecule analogs that target ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies ... locations, patients can visit Dr. Margulies to experience the best available orthodontic experience in ... title of "NJ Top Dentist"! , Orthodontics is the branch of dentistry that specializes ...
(Date:11/30/2015)... ... 2015 , ... ”Dying Words: The AIDS Reporting of Jeff Schmalz and How ... coincide with World AIDS Day. The multi-media project will be in audio documentary form ... he was dying of the disease. , A collaborative effort led by author, professor ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as ... more so for a child’s exposure limits. , The original Nov 2015 CR ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... KONG, Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September 2015 ... Income , 421,979 , 384,242 , ... , 34,719 , (18.3) Medical Insurance ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , ...
(Date:11/30/2015)... Calif. , Nov. 30, 2015 /PRNewswire/ ... the norm in U.S. medical imaging is ... increasingly popular accountable care payer-provider contracts are ... and, in their wake, alter provider-vendor relationships. ... payments will push forward new purchasing frameworks ...
(Date:11/30/2015)... Nov. 30, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... the development of oral drug delivery systems, announced today ... at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ... capsule, ORMD-0801, in China , ... . The agreements were signed at the Israel ...
Breaking Medicine Technology: